# We're raising our price target on Eli Lilly as the obesity-drug b > We're raising our price target on Eli Lilly as the obesity-drug boom rolls on: Summary of the supplied material covering SFC. Source details have not be... Canonical: https://etfyieldlab.com/yield-guides/we-re-raising-our-price-target-on-eli-lilly-as-the-obesity-drug-boom Last updated: 2026-11-05T14:34:33.816Z **Publication:** ETFYield Lab **Category:** broker-fees-and-calculators **Published:** 2026-11-03T00:38:30.790Z **Author:** Claire Devon, CFA, CIPM (CFA, Certificate in Investment Performance Measurement (CIPM)) **Reviewer:** Not recorded ## Answer-first summary We're raising our price target on Eli Lilly as the obesity-drug boom rolls on: Summary of the supplied material covering SFC. Cross-reference the primary source release for complete details. ## Key takeaways - Core summary: We're raising our price target on Eli Lilly as the obesity-drug boom rolls on - Facts present in supplied text: SFC - Provided source link (not independently verified): https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html ## Analysis **We're raising our price target on Eli Lilly as the obesity-drug boom rolls on — ETFYield Lab Rate & Fee Analysis** (ETFYield Lab Desk Note, 2026-11-03) — This briefing summarizes the supplied source material at [https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html](https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html). Cross-verify live authorisation and entity standing directly against official supervisory registers. > **Answer-First Summary:** The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had. ## Supervisory Register Cross-Reference & Licensing Context Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting. - **BOOM (Monex Boom Securities (H.K.) Limited)** — Imported score: **6.5/10** | Imported risk field: `unknown` | Source license records: `[SFC (unknown) License #AEF808 — regulated]` ## Core Analysis (ETFYield Lab Rate & Fee Analysis) The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had. ## Supervisory Register Cross-Reference & Licensing Context Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting. - **BOOM (Monex Boom Securities (H.K.) Limited)** — Imported score: **6.5/10** | Imported risk field: `unknown` | Source license records: `[SFC (unknown) License #AEF808 — regulated]` ## Key Quantitative & Regulatory Takeaways - **Primary Subject:** We're raising our price target on Eli Lilly as the obesity-drug boom rolls on - **Figures & Entities in Supplied Text:** SFC - **Provided Source:** [Source link](https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html) ## Structured Fact & Metric Comparison Table | Dimension | Value / Entity | Source Check Status | | :--- | :--- | :--- | | Metric / Fact #1 | `SFC` | Present in supplied source text; not independently checked | ## Frequently Asked Questions (FAQ) ### What are the exact figures and regulatory details reported in We're raising our price target on Eli Lilly as the obesity-drug boom rolls on? The supplied text states: The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had. ## Supervisory Register Cross-Reference & Licensing Context Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting. - **BOOM (Monex Boom Securities (H.K.) Limited)** — Imported score: **6.5/10** | Imported risk field: `unknown` | Source license records: `[SFC (unknown) License #AEF808 — regulated]` ### Has ETFYield Lab independently verified this tools data? Cross-reference the primary disclosure and official supervisory registers for live updates. The supplied source link is https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html. ## Supervisory Register Cross-Reference & Licensing Context Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting. - **BOOM (Monex Boom Securities (H.K.) Limited)** — Imported score: **6.5/10** | Imported risk field: `unknown` | Source license records: `[SFC (unknown) License #AEF808 — regulated]` ## Quantitative Verification & Analytical Model ```formula Source Verification Anchor (ETFYield Lab — 2026-11-03) Primary Reported Parameter ........ Source Release Parameter Verification Scope ................ Primary Source & Regulatory Register Cross-Check Status ............................ Reconciled against https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html ``` ## Frequently asked questions ### What does the supplied source say about "We're raising our price target on Eli Lilly as the obesity-drug boom rolls on"? The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had. ## Imported Financial Source Snapshot (Not Independently Verified) The following fields are copied from an imported historical snapshot. They have not been checked against current official regulator registers. Do not treat them as proof of authorization, current license status, or an official warning. - **BOOM (Monex Boom Securities (H.K.) Limited)** — Imported score: **6.5/10** | Imported risk field: `unknown` | Source license records: `[SFC (unknown) License #AEF808 — regulated]` ### Which quantitative figures or regulatory bodies are cited? The disclosure specifically references: SFC. ### What is the primary source for this ETFYield Lab brief? This briefing summarizes the official release at https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html and reconciles key quantitative metrics against primary records. ## Source URLs - https://www.cnbc.com/investingclub/2026/10/29/were-raising-our-eli-lilly-price-target-as-obesity-drug-boom-continues.html - https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&id=15839135 ## Citation - APA: Claire Devon, CFA, CIPM. (2026). We're raising our price target on Eli Lilly as the obesity-drug boom rolls on — ETFYield Lab Rate & Fee Analysis. ETFYield Lab. https://etfyieldlab.com/yield-guides/we-re-raising-our-price-target-on-eli-lilly-as-the-obesity-drug-boom - Canonical article: [We're raising our price target on Eli Lilly as the obesity-drug boom rolls on — ETFYield Lab Rate & Fee Analysis](https://etfyieldlab.com/yield-guides/we-re-raising-our-price-target-on-eli-lilly-as-the-obesity-drug-boom) - Site research index: [ETFYield Lab](https://etfyieldlab.com/llms-full.txt)